Lipella Pharma (LIPO) - Long-Term Debt to Capital Coefficient

Lipella Pharmaceuticals (LIPO) is developing unique methods for the targeted delivery of medications for cystitis, leveraging strict patent protection within a niche segment. Business growth is based on the success of LP-10 in bladder tumor therapy and collaborations with clinics. This price chart shows the metric at 0.00. Operational stability is ensured by diversified raw material supply chains and the establishment of warehouse reserves.

Lipella Pharmaceuticals' development of innovative drug delivery systems requires significant long-term investments. The ratio of long-term debt to equity reflects the balance between external financing and internal resources. A decrease in this coefficient indicates a reduction in debt load and a minimization of default risks. Excessively low leverage may suggest an underutilization of borrowed capital for growth. The trend of the long-term debt-to-equity ratio allows for an assessment of the company's financial stability.